AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04863885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.
Study NCT05826626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MindLenses Professional
Description: MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet
Study NCT05826626 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
Study NCT05377879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPT-IVF dosage
Description: Dosage predicted for each patient by the decision support tool OPTIVF
Study NCT04958772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim Megalabs
Description: Filgrastim Megalabs 5 μg/Kg/day, subcutaneous single dose
Study NCT04958772 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim Megalabs
Description: Filgrastim Megalabs 5 μg/Kg/day, subcutaneous single dose
Study NCT04958772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulokine
Description: Granulokine 5 μg/Kg/day, subcutaneous single dose
Study NCT04958772 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Granulokine
Description: Granulokine 5 μg/Kg/day, subcutaneous single dose
Study NCT05027464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving to COVID-19 Vaccine Acceptance Intervention
Description: The intervention utilizes a multi-pronged approach to increase Veteran vaccine acceptance. First, the research team will train Health Behavior Coordinators (HBCs) at VAI sites. HBCs will then train PACT teams at their site and Whole Health Coaches, Peer Specialists and other VA Staff in VAI strategies to use with unvaccinated Veterans. Whole Health Coaches, Peer Specialists and other VA Staff will conduct outreach calls, using strategies, with unvaccinated Veterans.
Study NCT05804474 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Observational study
Study NCT04587271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa oleifera (high dose)
Description: Mothers will receive 20 grams of moringa leaf powder in porridge consumed daily for three months.
Study NCT04587271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa oleifera (low dose)
Description: Children will receive 5-10 grams of moringa leaf powder in porridge consumed daily for three months.
Study NCT04587271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mothers and children will receive porridge with placebo.
Study NCT04708379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Nutrition and physical activity education.
Study NCT06231732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-frequency transcranial alternating current stimulation
Description: The experimental group received real stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 77.5Hz and 15mA
Study NCT06231732 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham high-frequency transcranial alternating current stimulation
Description: The the control group received sham stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 0mA
Study NCT05246397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex administration
Description: Sugammadex will be given in 50 mg increments every five minutes for reversal of neuromuscular blockade until reaching a train-of-four ratio of 0.9
Study NCT05203289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501 - higher concentration
Description: BI 695501 - higher concentration
Study NCT05203289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501 - lower concentration
Description: BI 695501 - lower concentration
Study NCT05677022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted motor activity
Description: 15-month adapted motor activity program based on a postural and functional analysis
Study NCT05275686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray
Description: Patients will use two sprays in each nostril twice a day for 6 weeks and additional 6 weeks (open label).
Study NCT05275686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: The Placebo is made of the following ingredients: Purified Water, Microcrystalline Cellulose RC-591, Dextrose, Anhydrous, EDTA Disodium Dihydrate, Benzalkonium Chloride Solution 50%, Polysorbate 80 (Tween 80, HP-LQ-(MH)), Sodium Hydroxide, and Hydrochloric Acid. Patients will use two sprays in each nostril twice a day
Study NCT04457141 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Effect of pelvic floor for the use of minimalist shoes versus shod in woman.
Description: Measure the activity of the pelvic floor and others muscles with EMG during treadmill running with different speeds and different shoes: minimalist and shod.
Study NCT05058794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow Restriction/Resistance Training
Description: During each exercise, only blood flow in the involved leg was restricted using an aneroid sphygmomanometer. Prior to exercise the cuff was placed on the most proximal portion of the limb and limb occlusion pressure (LOP) was calculated in the body position that the Blood flow Restriction (BFR) stimulus would be applied. Blood Flow Restriction BFR pressure was set at 50% occlusion. Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally. Participants will perform exercises 2 sets with 15 repetitions through 0 to 90 degrees.
Study NCT06563076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation
Description: supervised vestibular rehabilitation program
Study NCT06563076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Electrical Stimulation
Description: 80 Hz high frequency transcutaneous vestibular electrical stimulation (VES)
Study NCT06679036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvustat
Description: Fluvustat
Study NCT06679036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-8080
Description: HRS-8080
Study NCT06679036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209
Description: HRS-6209
Study NCT06679036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1358
Description: HRS-1358
Study NCT06678633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-Control® (experimental)
Description: Patients will receive intravesical therapy (1-2 hours) through T-Control®, a new Foley-type silicone catheter with an integrated fluid-control valve into the catheter's distal end, which has three positions.
Study NCT06678633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Folysil® (control)
Description: Patients will receive intravesical therapy (1-2 hours) through Folysil® Silicone catheter (Coloplast), the usual clinical practice in the participating center.
Study NCT06678815 — intervention group
Intervention type: OTHER
Intervention: Emergency response
Description: Those delivering or receiving emergency care from a CFR.
Study NCT06679322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androtriol Injection (High-dose group)
Description: Participants will receive 30 mL of Androtriol Injection per dose, administered every 12 hours for 7 consecutive days. Each infusion will be administered over a period of 30±5 minutes.
Study NCT05065216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue kallikrein
Description: DM199 administered by a single intravenous (IV) dose followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21
Study NCT05065216 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DM199 Solution for Injection
Description: Placebo administered by a single intravenous (IV) dose followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21.
Study NCT06679322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androtriol Injection (Low-dose group)
Description: Participants will receive 10 mL of Androtriol Injection combined with 20 mL of placebo (Hydroxypropyl Beta-Cyclodextrin Injection) per dose, administered every 12 hours for 7 consecutive days. Each infusion will be administered over a period of 30±5 minutes.
Study NCT06679322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxypropyl-β-cyclodextrin injection
Description: Participants will receive 30 mL of Hydroxypropyl-β-cyclodextrin injection per dose, administered every 12 hours for 7 consecutive days. Each infusion will be completed within 30±5 minutes.
Study NCT05580042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1101
Description: For each patient, once daily (QD)
Study NCT05058794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy Group
Description: Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally.participants will perform 2 sets with 15 repetitions in (0 to 90 degree.)
Study NCT05469789 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: As it is an observational study, no intervention is administered in this study.
Study NCT06371872 — intervention group
Intervention type: PROCEDURE
Intervention: total transfixing injury to the rotator cuff
Description: develop an appropriate prescription strategy with a view to improving patients' quality of life in the short, medium and long term in this condition
Study NCT05498909 — intervention group
Intervention type: OTHER
Intervention: Multidisciplinary joint diagnosis and treatment mode
Description: Multidisciplinary joint diagnosis and treatment mode,break down barriers and treat the heart and brain together
Study NCT04600973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technical assistance or team-based coaching
Description: Main comparison in delivering peri-operative preventive strategies against transmission and infection is one on one technical assistance or team-based coaching.
Study NCT06585384 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: etanercept and repeated contrast ultrasound
Description: Strategy combining 9 weeks of etanercept administration (50mg/week) with 5 weeks of repeated contrast ultrasound of 2 sessions per day, 5 days per week (from the fifth week of etanercept treatment)
Study NCT05380947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 - trial formulation 1 (TF1)
Description: BI 1810631 - trial formulation 1 (TF1)
Study NCT05380947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 - new formulation (NF)
Description: BI 1810631 - new formulation (NF)
Study NCT06285175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-REINVENT
Description: Tele-REINVENT consists of EMG-biofeedback of the affected arm to control games on a computer screen.
Study NCT05551208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluzopanib and bevacizumab
Description: fluzopanib and bevacizumab were used for maintenance treatment
Study NCT06324383 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention (videoconferencing)
Description: 1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
Study NCT05451108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCL Pectus Scaffold implantation and autologous fat grafting
Description: A small incision is made in the chest and pre-sternal pocked is defined. Following this, an empty scaffold is implanted at the site of the defect with skin closed directly over it. At the same stage, autologous fat transfer will be performed, harvesting fat from available donor sites such as the thighs and abdomen - depending on scaffold volume and patient morphology. The area will be infiltrated with local anaesthetic tumescent fluid, liposuction performed, and fat transferred to syringes for filtration prior to injection into the scaffold. Fat will not be processed beyond simple filtration to separate liquid from fat to be injected. The scaffold provides structural stability to the chest during the infiltration of the tissue inside the scaffold.
Study NCT06413303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential Classroom
Description: Experiential classroom emphasizes putting pregnant women at the center, based on their subjective willingness and previous knowledge and experience, creating an environment for free discussion, exchange, and reflection, and utilizing peer education to fully mobilize the subjective initiative of pregnant women. This approach allows them to explore, discuss, reflect, and learn autonomously, aiming to truly absorb, master, and apply theoretical knowledge.
Study NCT04948515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: genotyping of IL 17 and IL23
Study NCT04948515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: estimation of serum level of IL 17
Study NCT05769309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae block
Description: After induction, the patients will be administered bilateral Erector spinae block with 20 ml of 0.25 % bupivacaine
Study NCT05769309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl boluses of 0.5-to-1 µg/kg titrated according to haemodynamic parameters.
Study NCT05769309 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl
Description: fentanyl boluses of 0.5-to-1 µg/kg titrated according to haemodynamic parameters.
Study NCT06136195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavoglurant
Description: The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.
Study NCT04651361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinalbuphine sebacate
Description: Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
Study NCT04651361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
Study NCT06556550 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiation therapy
Description: stereotactic ablative radiation therapy in effective doses to each metastatic site
Study NCT06556550 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: palliative radiation therapy
Description: palliative radiation therapy (8 Gy/1 Fx, 3 Gy x 10-15 Fx, 4,5 Gy x 5 Fx)
Study NCT06556550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: prescribed drug line
Study NCT05380947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole sodium
Study NCT05375929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Description: Orally administered, abrocitinib 100 mg tablets QD
Study NCT05375929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Description: Orally administered, abrocitinib 200 mg tablets QD.
Study NCT06308237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RESISTED EXERCISES
Description: Patients will perform Chest plank for 30 seconds with 4 repetitions.~Then the Participants will perform these exercises for 1 minute each with 4 repetitions:~Wide grip lateral pull down , Lying triceps press, Sit up squats, Barbell curl each.~And will perform Thigh adduction for1 minute with 2 repititions.
Study NCT06308237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BALANCE EXERCISES
Description: Static and dynamic balance exercises will include:~Patients will perform Arm abduction holding a half-kg dumbbell, Opposite arm and leg in a quadruped position, Walking in a tandem stance(forward and backward), Turning and bending to the sides in a standing position, Pass through obstacles in a spiral, for 2 minutes each.~Then they will perform throwing a medicine ball to investigator and back while trying to maintain balance, Tandem stance, Walking backwards, Two-leg bridge as well as single (2 repetitions), Leg bridge (raising the other leg), walking on the heel, performing rhythmic movements while stepping on a circular environment and balance board exercises, for 1 minute each.~And will Walk up and down the stairs for 3 minutes.
Study NCT06395935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wecare (website)
Description: support feedback of qutionaire \& supply educational contents
Study NCT04393896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeChat-based integrative family intervention (WIFI)
Description: The WIFI program will include three key components: psycho-education through WeChat Official Account publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call
Study NCT06083571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Non-inferiority
Study NCT06083571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Non-inferiority
Study NCT06083571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Description: Adjunct
Study NCT06083571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine
Description: Adjunct
Study NCT06083571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Adjunct
Study NCT06083571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Adjunct
Study NCT06641518 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: a therapeutic modality employing electric current to relieve pain by activating peripheral nerves. The evolution of TENS units alongside technological advancements has led to user-friendly interfaces and enhanced portability, with units now small enough to be carried in a pocket.
Study NCT06641518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: a therapeutic modality employing electric current to relieve pain by activating peripheral nerves. The evolution of TENS units alongside technological advancements has led to user-friendly interfaces and enhanced portability, with units now small enough to be carried in a pocket.
Study NCT05821205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Persuasion
Description: Narratives will use anonymous testimonials from our prior work combined with open-source pictures. The researchers will ask participants to rate the testimonial message as a measure of engagement.
Study NCT05821205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reciprocity
Description: Researchers will track clicking on the gift card as a measure of engagement
Study NCT05821205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback
Description: Researchers will track clicking on a link and/or opening to review visual data as a source of engagement.
Study NCT05821205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment
Description: Providers will receive a commitment message and be asked to reply as a measure of engagement.
Study NCT06277219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAT010
Description: LAT010 monotherapy
Study NCT06277219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAT010 + ICI
Description: LAT010 combination with PD-1 inhibitor
Study NCT06465875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading a book
Description: Individuals in the intervention group will be read a storybook for three nights.
Study NCT06427044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anterior serratus block group
Description: Bupivacaine lipid 20mL (20mL 266mg bupivacaine liposomes) was ultrasound-guided for a single anterior serranus plane block
Study NCT05757726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Velocity pAVF system
Description: A second generation percutaneous AVF device that creates an AVF between the proximal radial artery and cubital perforating vein.
Study NCT05973045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative Hysteroscopy 24 Centigrade Degree
Description: Operative hysteroscopy will be performed at room temperature distention medium.